Clinical Trial Update: A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating gilteritinib in adults with advanced ALK-positive non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Gilteritinib (gilteritinib)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive | Phase 1 | Status: RECRUITING